Skip to main content
Equibles

ASND · Ascendis Pharma A/S · Earnings Call Transcripts & Audio

Track ASND — free

Use ASND with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ASND.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$227.83 -0.24 (-0.11%) At close · Sep 30
Russell 1000 member Rebalance outlook locked
Market Cap
$15.03B
Shares
65.78M
Volume · Sep 30 926.23K Avg daily vol (3M) 641.12K

Ascendis Pharma A/S Earnings Call Transcripts

Quarterly earnings calls for Ascendis Pharma A/S (ASND), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲1273.8% 15.29M EUR −168.96M EUR '22 Q3 22-09-30 ▲367.6% 22.90M EUR −207.42M EUR '22 Q4 22-12-31 ▲391.9% 33.59M EUR −110.91M EUR '23 Q1 23-03-31 ▲669.4% 47.39M EUR −121.43M EUR '23 Q2 23-06-30 ▲214.2% 48.03M EUR −162.22M EUR '23 Q3 23-09-30 ▲501.4% 137.70M EUR −86.88M EUR '23 Q4 23-12-31 ▲185.5% 95.89M EUR −131.03M EUR '24 Q1 24-03-31 ▼24% 36.00M EUR −109.38M EUR '24 Q2 24-06-30 ▲20.4% 57.83M EUR −99.20M EUR '24 Q3 24-09-30 ▲26.3% 173.92M EUR −38.47M EUR '24 Q4 24-12-31 ▲5.3% 100.95M EUR −94.63M EUR '25 Q1 25-03-31 ▲339% 158.04M EUR −38.85M EUR '25 Q2 25-07-12 ▲269.4% 213.63M EUR −60.99M EUR '25 Q3 25-09-30 ▲42.3% 247.50M EUR −33.56M EUR '25 Q4 26-01-08 ▲144.3% 246.60M EUR 629.34M EUR '26 Q1 26-04-08 LATEST ▲114.7% 339.29M EUR 206.97M EUR '26 Q2 26-08-13
Conference
Investor event
2026-09-15
Ascendis Pharma A/S (ASND) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-13
Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript
Confident tone Global commercialization infrastructure TransCon Combination Trial (COACH) results UVA Well (TransCon hGH) launch and competition
Revenue
339.29M EUR
▲ 114.7% YoY
Diluted EPS
2.83
Gross margin
91.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-08
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
Confident tone YORVIPATH commercial performance YUVIWEL launch (TransCon CNP) Competition in hypoparathyroidism
Revenue
246.60M EUR
▲ 144.3% YoY
Diluted EPS
9.75
Gross margin
92.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-01-08
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
Confident tone Yorvipath commercial launch and growth TransCon CNP and combination therapy in achondroplasia Skytrofa / TransCon Growth Hormone
Revenue
247.50M EUR*
▲ 42.3% YoY
Gross margin
90.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-09-30
Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript
Confident tone Eurvipath commercial launch Growth disorders portfolio Financial performance and profitability
Revenue
213.63M EUR
▲ 269.4% YoY
Gross margin
89.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-12
Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript
Confident tone YORVIPATH commercial launch TransCon CNP in achondroplasia Combination therapy / COACH trial
Revenue
158.04M EUR
▲ 339% YoY
Diluted EPS
-0.82
Gross margin
80.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript
Confident tone YORVIPATH U.S. launch performance Path to cash flow positive and financial outlook SKYTROFA franchise and label expansion
Revenue
100.95M EUR
▲ 5.3% YoY
Diluted EPS
-1.58
Gross margin
82.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript
Confident tone YORVIPATH U.S. launch and hypoparathyroidism opportunity TransCon CNP and achondroplasia SKYTROFA growth hormone franchise
Revenue
173.92M EUR*
▲ 26.3% YoY
Gross margin
91.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript
Confident tone SKYTROFA growth and U.S. commercial performance YORVIPATH U.S. launch readiness Full-year 2024 revenue guidance
Revenue
57.83M EUR
▲ 20.4% YoY
Diluted EPS
-1.72
Gross margin
80.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript
Confident tone SKYTROFA Market Access Reset YORVIPATH US Launch YORVIPATH Europe Commercialization
Revenue
36.00M EUR
▼ 24% YoY
Diluted EPS
-1.91
Gross margin
68.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Ascendis Pharma A/S (ASND) Q1 2024 Earnings Call Transcript
Confident tone SKYTROFA U.S. commercial performance TransCon CNP achondroplasia program TransCon PTH U.S. PDUFA and prelaunch
Revenue
95.89M EUR
▲ 185.5% YoY
Diluted EPS
-2.30
Gross margin
92.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Ascendis Pharma A/S (ASND) Q4 2023 Earnings Call Transcript
Revenue
137.70M EUR*
▲ 501.4% YoY
Gross margin
85.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Ascendis Pharma A/S (ASND) Q3 2023 Earnings Call Transcript
Revenue
48.03M EUR
▲ 214.2% YoY
Diluted EPS
-2.88
Gross margin
84.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Ascendis Pharma A/S (ASND) Q2 2023 Earnings Call Transcript
Revenue
47.39M EUR
▲ 669.4% YoY
Diluted EPS
-2.16
Gross margin
72.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript
Revenue
33.59M EUR
▲ 391.9% YoY
Diluted EPS
-1.98
Gross margin
86.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Ascendis Pharma A/S (ASND) Q4 2022 Earnings Call Transcript
Revenue
22.90M EUR*
▲ 367.6% YoY
Gross margin
77.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Ascendis Pharma A/S (ASND) Q3 2022 Earnings Call Transcript
Revenue
15.29M EUR
▲ 1273.8% YoY
Diluted EPS
-3.03
Gross margin
88.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Ascendis Pharma A/S (ASND) Q2 2022 Earnings Call Transcript
Revenue
6.16M EUR
▲ 502.7% YoY
Diluted EPS
-1.46
Gross margin
82.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Ascendis Pharma A/S (ASND) Q1 2022 Earnings Call Transcript
Revenue
6.83M EUR
▲ 815.3% YoY
Gross margin
37.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Ascendis Pharma A/S (ASND) Q4 2021 Earnings Call Transcript
Revenue
4.90M EUR*
▲ 815.3% YoY
Gross margin
28.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Ascendis Pharma A/S (ASND) Q3 2021 Earnings Call Transcript
Revenue
1.11M EUR
▼ 59.6% YoY
Gross margin
100.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Ascendis Pharma A/S (ASND) Q2 2021 Earnings Call Transcript
Revenue
1.02M EUR
▼ 28.8% YoY
Gross margin
100.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Ascendis Pharma A/S (ASND) Q1 2021 Earnings Call Transcript
Revenue
746,000 EUR
▼ 66.5% YoY
Gross margin
100.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Ascendis Pharma A/S (ASND) Q4 2020 Earnings Call Transcript
Revenue
535,000 EUR*
▼ 78.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Ascendis Pharma A/S (ASND) Q3 2020 Earnings Call Transcript
Revenue
2.76M EUR
▲ 22.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Ascendis Pharma A/S (ASND) Q2 2020 Earnings Call Transcript
Revenue
1.44M EUR
▼ 55.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Ascendis Pharma A/S (ASND) Q1 2020 Earnings Call Transcript
Revenue
2.23M EUR
▼ 58.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–27 of 27 earnings calls
Key facts CIK 1612042 CUSIP K08588103 13F (30d) 8 filings 8 filers Visit website Investor relations